Now, more than ever, investors and regulatory bodies are focused on pre-clinical process development and production capabilities as distinct precursors that can...
This week's Fierce LifeSci is brought to you by Miltenyi Biotec. Trouble viewing? Click here. |
Date: Thursday, April 15, 2021 Time: 2pm ET / 11am PT Duration: 1 Hour |
|
Biotechnology companies of all sizes face many challenges in the development of new cell and gene therapies. In this webinar, Mike O’Mara and Dr. Ian Gaudet will introduce the development and manufacturing approach used by Miltenyi Biotec and describe how a CDMO partner focused in process and analytical development can enable clinical readiness. Register Now Webinar topics include: Industry-leading technologies from Miltenyi Biotec along with a peek into the company’s new CDMO facility dedicated to co-development, tailored application fitment, and scalable cell processing Creating process robustness: Equipment, material and reagent considerations, including integrated solutions and process automation and control Why it’s important to consider commercial viability, as well as process and technology transfer risk, during pre-clinical development |
|
|
You are currently subscribed as [email protected] If you no longer wish to receive promotions from Fierce LifeSciences, simply unsubscribe. Refer to our Privacy Policy. Fierce LifeSciences is a division of Questex LLC. 685 3rd Ave 21st Floor New York, NY 10017 © 2020 Questex LLC. All Rights Reserved. Reproduction in whole or in part is prohibited without written permission. | |